Navigation Links
ThermoGenesis Reports 35 Percent Increase in First Quarter 2011 Revenues, Adds Strategic Advisor and Inks China Distribution Deal With Nanshan Memorial Medical Institute
Date:11/4/2010

he Company ended the first quarter of fiscal 2011 with $10.2 million in cash versus $10.7 million in cash at the end of fiscal 2010.

"For the fifth consecutive quarter, we have improved our bottom line performance.  We reduced our net loss by $2.1 million in the first quarter of fiscal 2011 compared to the first quarter of fiscal 2010. Absent the severance, restructuring and lease termination charges, we would have achieved a profitable quarter," said J. Melville Engle, Chairman and Chief Executive Officer.

"Our year-over-year revenue growth was driven by a 73 percent increase in AXP® AutoXpress™ (AXP) System bag set revenues.  However, it should be noted that AXP disposable sales were higher than the prior year same quarter by $1.2 million, due primarily to GE Healthcare (GEHC) increasing their inventory levels approximately $1.0 million to meet certain customer requirements.  We do not expect these inventory accumulations to continue into next quarter.  Without the inventory build, total sales would have been approximately $6.0 million, an increase of 15 percent versus a year ago," he said.

The Company also said it filed an updated 510(k) submission seeking market clearance from the FDA for the use of its Res-Q technology in the preparation of platelet rich plasma (PRP) from peripheral blood. In mid-October, ThermoGenesis announced a PRP cardiovascular license and distribution agreement for Res-Q with BioParadox, Inc., a newly-formed regenerative medicine company focusing on point-of-care cardiovascular therapies.

"The agreement with BioParadox places us squarely in the emerging field of PRP and is an important milestone in our initiative to create novel applications for our proprietary Res-Q technology," Engle said.

Company Awarded Federal Grant The Company also announced today that, on October 29th, it was awarded $244,000 in federal grant funding from the Department of Health and Human Service
'/>"/>

SOURCE ThermoGenesis Corp.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. ThermoGenesis Corp. to Announce First Quarter Fiscal 2011 Results on November 4, 2010
2. ThermoGenesis Announces Platelet Rich Plasma (PRP) Res-Q Cardiovascular Licensing Agreement
3. ThermoGenesis Announces Fourth Quarter Revenues of $7.2 Million; Reduces Net Loss to $171,000
4. ThermoGenesis Regains Compliance With NASDAQ Listing Rules
5. ThermoGenesis Announces Reverse Stock Split Effective on NASDAQ Capital Market August 27, 2010
6. ThermoGenesis Announces Agreement for Adipose Tissue Clinical Program
7. ThermoGenesis Names Jorge Artiles Vice President, Chief Quality and Regulatory Affairs Officer
8. ThermoGenesis Announces National Institute of Health Grant
9. ThermoGenesis Announces MXP Involvement in New Regenerative Medicine Initiatives
10. IRIDEX Reports Improved Third Quarter 2010 Financial Results
11. Genoptix Reports Operating Results for the Third Quarter and First Nine Months of 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... --  Millar, Inc. , a leader in catheter-based and ... of Craig Thummel , President/CEO and member of ... to the Company. The Company also announced its leadership ... Executive Management team as his successors. The Board of ... of Sales and Marketing, as President, and also a ...
(Date:6/30/2015)... 2015 Dipexium Pharmaceuticals, Inc. (Nasdaq: ... on the development and commercialization of Locilex® (pexiganan ... previously announced underwritten public offering of 1,480,000 shares ... over-allotment option in full to purchase an additional ... net proceeds to Dipexium are expected to be ...
(Date:6/30/2015)... , June 24, 2015 ... the addition of the "Global Array Instruments ... The global array instruments market to grow ... period 2014-2019 The global array instruments market ... protein microarrays, and others including tissue microarrays and ...
Breaking Medicine Technology:Millar, Inc. Announces Leadership Changes 2Millar, Inc. Announces Leadership Changes 3Dipexium Announces Closing of Public Offering of Common Stock 2Dipexium Announces Closing of Public Offering of Common Stock 3Global Array Instruments Market 2015-2019 - Advances in Personalized Medicines with Affymetrix, Agilent Technologies & Illumina Dominating 2
... Biosciences, Inc., a privately held company leading the development ... Steven L. Zelenkofske, D.O., F.A.C.C., Senior Vice President and ... College of Chest Physicians (ACCP) Coagulation and Heart Disease ...  The abstract is titled "Sustained Inhibition of Factor IXa ...
... JEDDAH, Saudi Arabia, Nov. 2, 2010 The Saudi ... it has signed an agreement with Varian Medical Systems ... for magnetic resonance-guided radiation therapy (MRgRT™). Under ... treatment solution that combines IMRIS, unique movable magnetic resonance ...
Cached Medicine Technology:Regado Biosciences, Inc. Presents the First-In-Human Clinical Experience with REG2 at the American College of Chest Physicians (ACCP) Coagulation and Heart Disease Sessions in Vancouver, BC, Canada on November 2, 2010 2Regado Biosciences, Inc. Presents the First-In-Human Clinical Experience with REG2 at the American College of Chest Physicians (ACCP) Coagulation and Heart Disease Sessions in Vancouver, BC, Canada on November 2, 2010 3Saudi Arabia's King Abdullah International Research Center Signs With Varian Medical Systems and IMRIS for Future Technology for Use in Radiotherapy 2Saudi Arabia's King Abdullah International Research Center Signs With Varian Medical Systems and IMRIS for Future Technology for Use in Radiotherapy 3Saudi Arabia's King Abdullah International Research Center Signs With Varian Medical Systems and IMRIS for Future Technology for Use in Radiotherapy 4
(Date:6/30/2015)... ... June 30, 2015 , ... ... Rehab”. The video focuses on the rehab center’s patients and their experiences at ... the best quality of services available. Each patient attests to the high rating, ...
(Date:6/30/2015)... ... June 30, 2015 , ... According to a June 15th report ... study how sensory stimuli can be used to “decrease children’s anxiety and negative responses ... with autism, will compare patient experience in a “typical dental environment” with one that ...
(Date:6/30/2015)... Long Beach, CA (PRWEB) , ... June 30, 2015 , ... ... Sea Skilled Nursing”, which features multiple patient and family member testimonials. Medicare rated the ... the country. Broadway plans to use the video to give future patients a firsthand ...
(Date:6/30/2015)... New York, NY (PRWEB) , ... June 30, ... ... international shipping when buying eyeglasses online , finally its here, ... and offer express shipping rates, for many location, ask about shipping with DHL ...
(Date:6/30/2015)... New York (PRWEB) , ... June 30, 2015 ... ... ( http://www.xareltolawsuit2015.com/ ) currently pending in a federal multidistrict litigation now underway in ... Court convenes its next monthly Status Conference. According to the Court’s calendar, that ...
Breaking Medicine News(10 mins):Health News:Patients of University Post-Acute Rehab Support Five-Star Rating in New Video 2Health News:New Study Aims to Determine if Sensory Stimuli can Ease Dental Anxiety in Children, Notes Medical Center Dental Care 2Health News:New Study Aims to Determine if Sensory Stimuli can Ease Dental Anxiety in Children, Notes Medical Center Dental Care 3Health News:Broadway by the Sea Video Promotes Top Quality Service 2Health News:Eyeglasses Online - Express Glasses Announcing New International Shipping Using DHL 2Health News:Progress of Federal Xarelto Lawsuits Pending in Multidistrict Litigation to Be Discussed During July 9th Status Conference 2Health News:Progress of Federal Xarelto Lawsuits Pending in Multidistrict Litigation to Be Discussed During July 9th Status Conference 3
... the cost of such tests is a potential stumbling block, ... the heart arteries for calcium deposits can help predict future ... that adding such scans to routine checkups would be worth ... of potential heart trouble, said Dr. Diane Bild, deputy director ...
... Michael D. Farley has,joined the Lupus ... Washington,DC as the organization,s Chief Operating Officer, ... overall organizational administration and,field development. Farley has ... including serving most recently as the,interim CEO ...
... Inc.,(Nasdaq: EMAG ), a leader in ... healthcare networks, announced today that its,HeartSuite(TM) VERICIS(R) ... for,Cardiology PACS*. HeartSuite is Emageon,s comprehensive suite ... information,management, hemodynamic monitoring, advanced visualization and content,management. ...
... PURCELLVILLE, Va., March 26 At a panel,discussion ... Force Colonel,Mike Turner, a candidate for U.S. Congress ... for Professor Judy Feder, his opponent,in the June ... Frank,Wolf in what is expected to be a ...
... Courses Improve Patient Care and Address State Regulations, ... Care Compliance,Strategies, Inc.), the leading provider of online ... with University,HealthSystem Consortium (UHC) to deliver a suite ... 11 courses with multimedia content and,healthcare specific case ...
... of Other Medicare Providers at Risk, WASHINGTON, ... drug plans (PDPs) pay drugstores twice as fast,as ... and its,beneficiaries at least $3.3 billion over the ... (PwC) that was commissioned by the,Pharmaceutical Care Management ...
Cached Medicine News:Health News:Calcium Scans Help Predict Coronary Risk 2Health News:Michael D. Farley Appointed Chief Operating Officer of Lupus Foundation of America, Inc. 2Health News:Emageon Receives 'Best in KLAS' Cardiology PACS Award 2Health News:Democrat Mike Turner Backs Single-Payer Healthcare; Opponent Feder Undecided 2Health News:HCCS Partners With UHC to Deliver Cultural Competency Courses 2Health News:HCCS Partners With UHC to Deliver Cultural Competency Courses 3
The URCA (Uric acid) method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of uric acid in serum, plasma and urine....
For the quantitative in vitro determination of apolipoprotein A-1 (apo A-1) in serum and plasma. For use as an aid if assessing the risk of coronary artery disease....
The GGT method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of g-glutamyl transferase activity in serum and plasma...
For the quantitative in vitro determination of Triglycerides in serum and plasma....
Medicine Products: